Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth

Wood, N., Marshall, H., White, O.J., Holt, P.G. and McIntyre, P. (2014) Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth. Pediatric Infectious Disease Journal, 33 5: 511-517. doi:10.1097/INF.0000000000000246


Author Wood, N.
Marshall, H.
White, O.J.
Holt, P.G.
McIntyre, P.
Title Antibody and cell-mediated immunity to pertussis 4 years after monovalent acellular pertussis vaccine at birth
Journal name Pediatric Infectious Disease Journal   Check publisher's open access policy
ISSN 1532-0987
0891-3668
Publication date 2014-01-01
Sub-type Article (original research)
DOI 10.1097/INF.0000000000000246
Open Access Status Not yet assessed
Volume 33
Issue 5
Start page 511
End page 517
Total pages 7
Place of publication Philadelphia, PA, U.S.A.
Publisher Lippincott Williams and Wilkins
Language eng
Subject 2735 Pediatrics, Perinatology, and Child Health
2725 Infectious Diseases
2726 Microbiology (medical)
Abstract BACKGROUND:: In a previous study, we found that monovalent acellular pertussis (aP) vaccine at birth and 1 month achieves higher IgG antibody (Ab) levels to pertussis toxoid (PT), filamentous hemagglutinin (FHA) and pertactin by 8 weeks, when compared with controls. Here, we report antibody and cell-mediated immune responses to 4 years of age. METHODS:: IgG Ab to PT, filamentous hemagglutinin and pertactin, diphtheria (D) and tetanus (T) was measured in the 3 groups (aP vaccine at birth and 1 month, aP birth only and no aP) at 2 years of age and before and after DTaP-inactivated polio vaccine (DTaP-IPV) at 4 years of age. Cell-mediated immune responses to pertussis vaccine antigens were measured at 2 years of age. Adverse events following DTaP-IPV were recorded. RESULTS:: Of 74 subjects, 52 (70%) were available for follow up. Overall, 11 (21%) had detectable PT IgG at 2 years, decreasing to 10% before 4-year-old booster compared with 100% at 8 months of age. After the 4-year booster, pertussis antigen IgG levels were similar, but there was a trend to lower PT IgG levels in birth aP infants (geometric mean concentrations: 28.7 EI.U/mL) compared with controls (geometric mean concentrations: 53.6 EI.U/mL). The cytokine responses to pertussis antigen stimulation were higher in aP recipients at 2 years of age. There was no difference in injection site reactions among groups following the DTaP-IPV booster at 4 years of age. CONCLUSIONS:: In the longest reported follow-up of infants who received aP vaccine at birth, we found a trend to lower PT IgG antibodies post booster compared with receipt of first dose of aP-containing vaccine at 8 weeks of age. Short- and long-term antibody responses with and without prior maternal pertussis vaccination are crucial for further evaluation of this strategy for preventing severe early pertussis.
Keyword acellular pertussis vaccine
birth
immunogenicity
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2015 Collection
Queensland Children's Medical Research Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 20 May 2014, 12:26:17 EST by System User on behalf of School of Medicine